Thomas “Rusty” Pool has spent more than four decades inside IVF laboratories, watching the field move from single digit pregnancy rates to over 60% today. His work has shaped how embryologists think about metabolism, lab systems, and embryo development. In this conversation, he reflects on the science behind embryology, the importance of laboratory fundamentals, and the pressures shaping modern IVF programs.

David Pépin, PhD, Oviva Therapeutics, and Granata Bio featured in Time magazine series on The Age of Longevity

Granata Bio’s Chief Regulatory Officer, CMC, was featured in the January 2026 issue of Regulatory Rapporteur, exploring how confidence-based, risk-proportionate regulatory pathways can enable innovation across complex products—from brain-computer interfaces to digital CMC—without compromising patient safety.

Emerging research shows AMH is more than a marker of ovarian reserve, revealing an addressable therapeutic target with applications across menopause, oncofertility, and IVF stimulation.

Granata Bio announced strong momentum in its pivotal Phase III clinical study, with multiple subjects already screened to evaluate the safety and efficacy of its investigational gonadotropin product for use in assisted reproductive technology (ART). The GRACE multicenter study is now actively enrolling across leading fertility centers throughout the United States.

David Pepin, PhD, is reimagining the role AMH may play in future infertility treatment, aiming to give care teams expanded options in the clinic.

Reproductive health is a therapeutic area that has seen too little progress for too long.

Granata Bio Corporation and Georgetown Equity Partners Announce Joint Venture to Develop a Novel, Next-Generation Form of Follicle-Stimulating Hormone (FSH)

CEO Evan Sussman worked with The Boston Globe to highlight how a lack of innovation in reproductive health has negatively impacted affordability in IVF treatments and how Granata Bio and others are working to make infertility medications more accessible for those on the path to parenthood.

IBSA Group and Granata Bio announces first patient screened in pivotal PROGRESS clinical trial of Progesterone-IBSA